The Pharmacokinetics of Subcutaneous Enoxaparin in End‐Stage Renal Disease

• DOI: 10.1592/phco.21.2.169.34113
• Publication Date: 2004-06-07T09:03:57Z
• Authors: Donald F. Brophy; Lori D. Wazny; Todd W. B. Gehr; Thomas J. Comstock; Jürgen Venitz
• Keywords: Pharmacodynamics; Enoxaparin sodium; Dose

To evaluate the pharmacokinetics of enoxaparin in end-stage renal disease (ESRD), and determine if dosage reduction is necessary to maintain antifactor Xa activity concentrations within therapeutic range.Prospective, single-dose pharmacokinetic study.University-affiliated general clinical research center.Eight nonthrombosed patients with ESRD requiring hemodialysis.All subjects received a single dose sodium 1 mg/kg subcutaneously had serial plasma measured over 24 hours.The were determined from concentrations, various multiple-dose regimens simulated. After administration drug, total body clearance was 14.6 ml/minute there 2-fold prolongation half-life compared values reported healthy subjects. All other parameters similar those chronic insufficiency. An accumulation ratio 1.6 estimated for dosing interval every 12 hours based on pharmacokinetics. When simulated predict average steady-state activity, standard dosages 1.5 resulted range.Based has little effect enoxaparin, adjustments are unnecessary.